- Invited speaker presentation
- Open Access
TTR amyloidosis: a scientific journey since Andrade
© Saraiva 2015
Published: 2 November 2015
Mário Corino de Andrade described in 1952 in the journal “Brain” the first form of an hereditary amyloidosis, Famlial Amyloidotic Polyneuropathy, FAP - affecting the peripheral nervous system, also known as Andrade´s disease. In 1939 Andrade observed different patients complaining of loss of sensitivity to temperature and pain. These symptoms affected other families in the area, namely fisherman who complained of loss of sensitivity in their feet when touching the ropes of their small fishing boats. Andrade with the extraordinary intuition that all collaborators admired, realized the clinical symptoms deviated from what he had seen until then.
Andrade suspected he was in the presence of a rare hereditary disease. To understand in depth what he considered new, he asked the collaboration of experts in different fields, like genetics, pathology, confirming the genetic nature of the disease and the presence of systemic amyloid deposits, particularly in the peripheral nervous system. Since this seminal work, the explosion of molecular biology tools gave us today perspectives for therapies.
Some of the concepts and hypotheses put forward then with basic equipment and techniques available in the last century evolved tremendously giving us molecular and cellular in-depth knowledge; Andrade´s vision is still updated but need urgent clarification if we want to move towards urgent efficiency therapies of the disease. This lecture will exemplify one case where we still stand behind a black box despite access to modern know-how.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.